Skip to main content

Advertisement

Table 1 Selected small cell lung cancer trials

From: Immunotherapy in extensive small cell lung cancer

Name of trial Phase Therapy mOS mPFS ORR (%) Ref
CheckMate 032 (relapsed extensive stage) 1/2 Nivolumab 3 mg/kg NR NR 10 [7]
Nivolumab 1 mg/kg + Ipilimumab 1 mg/kg NR NR 33
Nivolumab 1 mg/kg + Ipilimumab 3 mg/kg NR NR 23
Nivolumab 3 mg/kg + Ipilimumab 1 mg/kg NR NR 19
IMpower 133 (treatment naive extensive stage) 3 Carboplatin/Etoposide 4 cycles 10 4.3   [11]
Carboplatin/Etoposide/Atezolizumab 4 cycles—Atezolizumab maintenance 12 5.2  
Name of trial Ongoing trials
Phase Therapy Primary endpoints Secondary endpoints Ref  
CheckMate 331 (relapsed) 3 Nivolumab OS PFS, ORR [12]  
Topotecan
CheckMate 451 (maintenance after response to platinum doublet 3 Nivolumab OS PFS [13]  
Nivolumab + Ipilimumab
Placebo
KeyNote 158 (relapsed/refractory) 2 Keytruda ORR OS, PFS, DOR [14]  
KeyNote 028 (extensive stage) 1 Keytruda ORR OS, PFS, DOR [15]  
  1. mOS median overall survival, mPFS median progression free survival, ORR objective response rate, Ref reference, NR not reached, OS overall survival, PFS progression free survival, DOR duration of response